Safety, immunogenicity and immune-persistence of heterologous prime-boost immunization with BBIBP-CorV and ZF2001 against SARS-CoV-2 in healthy adults aged 18 years or older

• Main Authors: Yingping Chen (Author), Xinpei Zhang (Author), Lihui Gong (Author), Zhenzhen Liang (Author), Xiaosong Hu (Author), Bo Xing (Author), Yuting Liao (Author), Lingfeng Yuan (Author), Gang Chen (Author), Huakun Lv (Author)
• Format: Book
• Published: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background Because SARS-CoV-2 mutations and immunity wane over time, a third dose of heterologous COVID-19 vaccine is proposed for individuals primed with inactivated COVID-19 vaccine. Research design and methods We conducted a single-center, open-label trial to assess the safety, immunogenicity, an...